Compare Heron Therapeutics Inc (HRTX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs State Street PDR S&P Retail ETF — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while State Street PDR S&P Retail ETF trades at $84.09 (market cap $389.66M). The key difference: State Street PDR S&P Retail ETF is far larger — about 5.7× Heron Therapeutics Inc's market cap, and State Street PDR S&P Retail ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| HRTX | XRT | |
|---|---|---|
Market Cap | $68.01M | $389.66M |
Volume | 1,891,941 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $92.35 |
52-Week Low | $0.27 | $77.28 |
Typical Hold Time | 35 Days | 45 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
XRT (SPDR S&P Retail ETF) trades at $84.09, up 1.42% with a bullish technical signal despite mixed moving averages. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with Seeking Alpha noting underperformance against IVV year-to-date. Recent retail sales data shows volatility, with August rebounding 1.2% after July's unexpected 0.6% decline, creating uncertainty for the retail sector outlook.
The retail ETF's performance hinges on consumer resilience amid economic pressures, with holiday sales projections exceeding $1 trillion offering potential upside. However, persistent inflation and rate concerns present significant risks, while technical indicators show overbought conditions with RSI at 84.45 suggesting near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
